1 Min Read
Sept 29 (Reuters) - Insys Therapeutics Inc
* Insys Therapeutics files new drug application (NDA) for buprenorphine sublingual spray with FDA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.